Immunoinformatics analysis of the proteins MPT83 and MPT51 to design a possible chimeric vaccine against Mycobacterium tuberculosis.
Innovative bioinformatics analysis identifies a promising chimeric vaccine against tuberculosis, combining key proteins MPT83 and MPT51 to elicit a robust immune response with high antigenicity and no allergenicity.
This study used immunoinformatics and reverse vaccinology to evaluate the potential of Mycobacterium tuberculosis proteins MPT83 and MPT51 for vaccine development. Bioinformatics tools were employed to predict T and B cell epitopes, assess allergenicity and antigenicity, and model the tertiary structure of a chimeric vaccine candidate. The results demonstrate that a fusion of the N-terminal region of MPT83 and the C-terminal region of MPT51, combined with an adjuvant, exhibits excellent immunological properties and can be successfully expressed in E. coli, paving the way for future in vivo studies. This innovative approach holds promise for the design of an effective and safe tuberculosis vaccine.